{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:03:40Z","timestamp":1778605420236,"version":"3.51.4"},"reference-count":65,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n<jats:title> Background:<\/jats:title>\n<jats:p>Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic\nsteatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in\nthe pathogenesis of NAFLD\/NASH.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p> To investigate the prevalence of NAFLD\/NASH in 5,400 military personnel and evaluate\nthe effect of treatment with 3 statins on NAFLD\/NASH using 2 non-invasive scores [NAFLD Activity\nScore (NAS); Fibrosis-4 score (FIB-4)].<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>During the mandatory annual medical check-up, military personnel underwent a clinical\nand laboratory evaluation. Participants with NAFLD\/NASH were randomized into 4 groups\n(n=151 each): diet-exercise, atorvastatin, rosuvastatin, or pitavastatin for 1 year (i.e., until the next\nroutine evaluation).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>From all the participants, 613 had NAFLD\/NASH (prevalence 11.3 vs 39.8% in the general\npopulation, p&lt;0.001), and a total of 604 consented to participate in the study. After a year of\ntreatment, the diet-exercise group showed no significant changes in both scores (NAS 4.98 baseline\nvs. 5.62, p=0.07; FIB-4 3.42 vs. 3.52, p=0.7). For the atorvastatin group, both scores were reduced\n(NAS 4.97 vs 1.95, p&lt;0.001, FIB-4 3.56 vs 0.83, p&lt;0.001), for rosuvastatin (NAS 5.55 vs\n1.81, p&lt;0.001, FIB-4 3.61 vs 0.79, p&lt;0.001), and for pitavastatin (NAS 4.89 vs 1.99, p&lt;0.001,\nFIB-4 3.78 vs 0.87, p&lt;0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions :<\/jats:title>\n<jats:p>Atorvastatin, rosuvastatin, and pitavastatin have a beneficial and safe effect in\nNAFLD\/NASH patients as recorded by the improvement in the NAS (representing NAFLD activity)\nand FIB-4 (representing liver fibrosis) scores. Since both those with and without NAFLD\/-\nNASH shared several baseline characteristics, genetics may play a role in the pathogenesis of\nNAFLD\/NASH and its treatment with statins.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161118666201015152921","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T06:28:07Z","timestamp":1602829687000},"page":"572-581","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease\/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?"],"prefix":"10.2174","volume":"19","author":[{"given":"Georgios","family":"Sfikas","sequence":"first","affiliation":[{"name":"1st Department of Internal Medicine, 424 General Military Training Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Psallas","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, 424 General Military Training Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Koumaras","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, 424 General Military Training Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Imprialos","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University School of Medicine, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Perdikakis","sequence":"additional","affiliation":[{"name":"Department of Ultrasonography, 424 General Military Training Hospital, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University School of Medicine, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Giouleme","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University School of Medicine, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asterios","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University School of Medicine, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios G.","family":"Athyros","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University School of Medicine, Thessaloniki,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"Angulo P.","year":"2002","unstructured":"Angulo P.; Nonalcoholic fatty liver disease. N Engl J Med 2002,346(16),1221-1231","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"Davison BA","year":"2020","unstructured":"Davison BA; Harrison SA; Cotter G; Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials 2020,73(6),1322-1332"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cgh.2010.03.025","volume":"8","author":"Seeff L.B.","year":"2010","unstructured":"Seeff L.B.; Everson G.T.; Morgan T.R.; Curto T.M.; Lee W.M.; Ghany M.G.; Shiffman M.L.; Fontana R.J.; Di Bisceglie A.M.; Bonkovsky H.L.; Dienstag J.L.; Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol HALT\u2013C Trial Group2010,8(10),877-883","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"Ratziu V.","year":"2005","unstructured":"Ratziu V.; Charlotte F.; Heurtier A.; Gombert S.; Giral P.; Bruckert E.; Grimaldi A.; Capron F.; Poynard T.; Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology LIDO Study Group2005,128(7),1898-1906","journal-title":"Gastroenterology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Younossi Z.","year":"2019","unstructured":"Younossi Z.; Stepanova M.; Ong J.P.; Jacobson I.M.; Bugianesi E.; Duseja A.; Eguchi Y.; Wong V.W.; Negro F.; Yilmaz Y.; Romero-Gomez M.; George J.; Ahmed A.; Wong R.; Younossi I.; Ziayee M.; Afendy A.; Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol Global Nonalcoholic Steatohepatitis Council2019,17(4),748-755","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"Kleiner D.E.","year":"2005","unstructured":"Kleiner D.E.; Brunt E.M.; Van Natta M.; Behling C.; Contos M.J.; Cummings O.W.; Ferrell L.D.; Liu Y.C.; Torbenson M.S.; Unalp-Arida A.; Yeh M.; McCullough A.J.; Sanyal A.J.; Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology Nonalcoholic Steatohepatitis Clinical Research Network2005,41(6),1313-1321","journal-title":"Hepatology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"Vilar-Gomez E.","year":"2018","unstructured":"Vilar-Gomez E.; Chalasani N.; Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018,68(2),305-315","journal-title":"J Hepatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"Angulo P.","year":"2007","unstructured":"Angulo P.; Hui J.M.; Marchesini G.; Bugianesi E.; George J.; Farrell G.C.; Enders F.; Saksena S.; Burt A.D.; Bida J.P.; Lindor K.; Sanderson S.O.; Lenzi M.; Adams L.A.; Kench J.; Therneau T.M.; Day C.P.; The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007,45(4),846-854","journal-title":"Hepatology"},{"key":"ref=9","first-page":"251","volume":"5","author":"Mohammadi A.","year":"2012","unstructured":"Mohammadi A.; Bazazi A.; Maleki-Miyandoab T.; Ghasemi-Rad M.; Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding. Int J Clin Exp Med 2012,5(3),251-256","journal-title":"Int J Clin Exp Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"Athyros V.G.","year":"2010","unstructured":"Athyros V.G.; Tziomalos K.; Gossios T.D.; Griva T.; Anagnostis P.; Kargiotis K.; Pagourelias E.D.; Theocharidou E.; Karagiannis A.; Mikhailidis D.P.; Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet GREACE Study Collaborative Group2010,376(9756),1916-1922","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","volume":"168","author":"Tikkanen M.J.","year":"2013","unstructured":"Tikkanen M.J.; Fayyad R.; Faergeman O.; Olsson A.G.; Wun C.C.; Laskey R.; Kastelein J.J.; Holme I.; Pedersen T.R.; Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol IDEAL Investigators2013,168(4),3846-3852","journal-title":"Int J Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/15701611113119990009","volume":"12","author":"Kargiotis K.","year":"2014","unstructured":"Kargiotis K.; Katsiki N.; Athyros V.G.; Giouleme O.; Patsiaoura K.; Katsiki E.; Mikhailidis D.P.; Karagiannis A.; Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014,12(3),505-511","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=13","unstructured":"US medicine. The voice of federal medicine. Available at:"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"Kleiner D.E.","year":"2019","unstructured":"Kleiner D.E.; Brunt E.M.; Wilson L.A.; Behling C.; Guy C.; Contos M.; Cummings O.; Yeh M.; Gill R.; Chalasani N.; Neuschwander-Tetri B.A.; Diehl A.M.; Dasarathy S.; Terrault N.; Kowdley K.; Loomba R.; Belt P.; Tonascia J.; Lavine J.E.; Sanyal A.J.; Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open Nonalcoholic Steatohepatitis Clinical Research Network2019,2(10),e1912565","journal-title":"JAMA Netw Open"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"Sterling R.K.","year":"2006","unstructured":"Sterling R.K.; Lissen E.; Clumeck N.; Sola R.; Correa M.C.; Montaner J.; S Sulkowski M.; Torriani F.J.; Dieterich D.T.; Thomas D.L.; Messinger D.; Nelson M.; Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology APRICOT Clinical Investigators2006,43(6),1317-1325","journal-title":"Hepatology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/157016111797484152","volume":"9","author":"Katsiki N.","year":"2011","unstructured":"Katsiki N.; Athyros V.G.; Karagiannis A.; Mikhailidis D.P.; Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011,9(6),698-705","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.3748\/wjg.v16.i31.3944","volume":"16","author":"Zois C.D.","year":"2010","unstructured":"Zois C.D.; Baltayiannis G.H.; Bekiari A.; Goussia A.; Karayiannis P.; Doukas M.; Demopoulos D.; Mitsellou A.; Vougiouklakis T.; Mitsi V.; Tsianos E.V.; Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol 2010,16(31),3944-3949","journal-title":"World J Gastroenterol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3748\/wjg.v21.i3.794","volume":"21","author":"Chen L.Z.","year":"2015","unstructured":"Chen L.Z.; Xin Y.N.; Geng N.; Jiang M.; Zhang D.D.; Xuan S.Y.; PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol 2015,21(3),794-802","journal-title":"World J Gastroenterol"},{"key":"ref=19","unstructured":"Clinical Trials .gov. Available at:"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1463-1326.2004.00409.x","volume":"7","author":"Athyros V.G.","year":"2005","unstructured":"Athyros V.G.; Bouloukos V.I.; Pehlivanidis A.N.; Papageorgiou A.A.; Dionysopoulou S.G.; Symeonidis A.N.; Petridis D.I.; Kapousouzi M.I.; Satsoglou E.A.; Mikhailidis D.P.; The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab MetS-Greece Collaborative Group2005,7(4),397-405","journal-title":"Diabetes Obes Metab"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.2337\/dc06-0138","volume":"29","author":"Schulz L.O.","year":"2006","unstructured":"Schulz L.O.; Bennett P.H.; Ravussin E.; Kidd J.R.; Kidd K.K.; Esparza J.; Valencia M.E.; Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006,29(8),1866-1871","journal-title":"Diabetes Care"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10545-017-0013-y","volume":"41","author":"Bloom K.","year":"2018","unstructured":"Bloom K.; Mohsen A.W.; Karunanidhi A.; El Demellawy D.; Reyes-M\u00fagica M.; Wang Y.; Ghaloul-Gonzalez L.; Otsubo C.; Tobita K.; Muzumdar R.; Gong Z.; Tas E.; Basu S.; Chen J.; Bennett M.; Hoppel C.; Vockley J.; Investigating the link of ACAD10 deficiency to type 2 diabetes mellitus. J Inherit Metab Dis 2018,41(1),49-57","journal-title":"J Inherit Metab Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcmgh.2019.02.002","volume":"7","author":"Zhang X.","year":"2019","unstructured":"Zhang X.; Zhang J.; Sun H.; Liu X.; Zheng Y.; Xu D.; Wang J.; Jia D.; Han X.; Liu F.; Nie J.; Shi Y.; Defective Phosphatidylglycerol Remodeling Causes Hepatopathy, Linking Mitochondrial Dysfunction to Hepatosteatosis. Cell Mol Gastroenterol Hepatol 2019,7(4),763-781","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12998\/wjcc.v6.i8.167","volume":"6","author":"Wang J.Z.","year":"2018","unstructured":"Wang J.Z.; Cao H.X.; Chen J.N.; Pan Q.; PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases 2018,6(8),167-175","journal-title":"World J Clin Cases"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000375353","volume":"33","author":"Traussnigg S.","year":"2015","unstructured":"Traussnigg S.; Kienbacher C.; Halilbasic E.; Rechling C.; Kazemi-Shirazi L.; Hofer H.; Munda P.; Trauner M.; Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Dig Dis 2015,33(4),598-607","journal-title":"Dig Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bbalip.2017.12.002","volume":"1863","author":"Zhang W.","year":"2018","unstructured":"Zhang W.; Yang X.; Chen Y.; Hu W.; Liu L.; Zhang X.; Liu M.; Sun L.; Liu Y.; Yu M.; Li X.; Li L.; Zhu Y.; Miao Q.R.; Han J.; Duan Y.; Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. Biochim Biophys Acta Mol Cell Biol Lipids 2018,1863(2),177-190","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/hep.28747","volume":"64","author":"Hu W.","year":"2016","unstructured":"Hu W.; Zhang W.; Chen Y.; Rana U.; Teng R.J.; Duan Y.; Liu Z.; Zhao B.; Foeckler J.; Weiler H.; Kallinger R.E.; Thomas M.J.; Zhang K.; Han J.; Miao Q.R.; Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway. Hepatology 2016,64(5),1559-1576","journal-title":"Hepatology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/eurheartj\/ehz393","volume":"40","author":"Leisegang M.S.","year":"2019","unstructured":"Leisegang M.S.; Bibli S.I.; G\u00fcnther S.; Pfl\u00fcger-M\u00fcller B.; Oo J.A.; H\u00f6per C.; Seredinski S.; Yekelchyk M.; Schmitz-Rixen T.; Sch\u00fcrmann C.; Hu J.; Looso M.; Sigala F.; Boon R.A.; Fleming I.; Brandes R.P.; Pleiotropic effects of laminar flow and statins depend on the Kr\u00fcppel-like factor-induced lncRNA MANTIS. Eur Heart J 2019,40(30),2523-2533","journal-title":"Eur Heart J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-018-0004-7","volume":"556","author":"Lin S.","year":"2018","unstructured":"Lin S.; Nascimento E.M.; Gajera C.R.; Chen L.; Neuh\u00f6fer P.; Garbuzov A.; Wang S.; Artandi S.E.; Distributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury. Nature 2018,556(7700),244-248","journal-title":"Nature"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/cells9030590","volume":"9","author":"Overi D.","year":"2020","unstructured":"Overi D.; Carpino G.; Franchitto A.; Onori P.; Gaudio E.; Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells 2020,9(3),590","journal-title":"Cells"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"Tilg H.","year":"2010","unstructured":"Tilg H.; Moschen A.R.; Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010,52(5),1836-1846","journal-title":"Hepatology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2020.03.006","volume":"73","author":"Liu Z.","year":"2020","unstructured":"Liu Z.; Zhang Y.; Graham S.; Wang X.; Cai D.; Huang M.; Pique-Regi R.; Dong X.C.; Chen Y.E.; Willer C.; Liu W.; Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol 2020,73(2),263-276","journal-title":"J Hepatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1185\/030079902125000787","volume":"18","author":"Athyros V.G.","year":"2002","unstructured":"Athyros V.G.; Papageorgiou A.A.; Mercouris B.R.; Athyrou V.V.; Symeonidis A.N.; Basayannis E.O.; Demitriadis D.S.; Kontopoulos A.G.; Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002,18(4),220-228","journal-title":"Curr Med Res Opin"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrcardio.2010.219","volume":"8","author":"Mearns B.M.","year":"2011","unstructured":"Mearns B.M.; Pharmacotherapy: Statins are safe in NAFLD. Nat Rev Cardiol 2011,8(2),65","journal-title":"Nat Rev Cardiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.metabol.2016.10.006","volume":"66","author":"Athyros V.G.","year":"2017","unstructured":"Athyros V.G.; Katsiki N.; Mikhailidis D.P.; Statins and non-alcoholic steatohepatitis. Metabolism 2017,66,e1-e2","journal-title":"Metabolism"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1185\/03007995.2013.855192","volume":"30","author":"Athyros V.G.","year":"2014","unstructured":"Athyros V.G.; Katsiki N.; Karagiannis A.; Mikhailidis D.P.; Are statins \u2018IDEAL\u2019 for non-alcoholic fatty liver disease? Curr Med Res Opin 2014,30(2),229-231","journal-title":"Curr Med Res Opin"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2174\/157016111797484080","volume":"9","author":"Athyros V.G.","year":"2011","unstructured":"Athyros V.G.; Ganotakis E.; Kolovou G.D.; Nicolaou V.; Achimastos A.; Bilianou E.; Alexandrides T.; Karagiannis A.; Paletas K.; Liberopoulos E.N.; Tziomalos K.; Petridis D.; Kakafika A.; Elisaf M.S.; Mikhailidis D.P.; Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative2011,9(6),647-657","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1152\/ajpgi.00101.2017","volume":"312","author":"Athyros V.G.","year":"2017","unstructured":"Athyros V.G.; Katsiki N.; Mikhailidis D.P.;  Am J Physiol Gastrointest Liver Physiol 2017,312(6),681-682","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3892\/ijmm.2016.2766","volume":"38","author":"Yokohama K.","year":"2016","unstructured":"Yokohama K.; Fukunishi S.; Ii M.; Nakamura K.; Ohama H.; Tsuchimoto Y.; Asai A.; Tsuda Y.; Higuchi K.; Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice. Int J Mol Med 2016,38(5),1499-1506","journal-title":"Int J Mol Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"Dongiovanni P.","year":"2015","unstructured":"Dongiovanni P.; Petta S.; Mannisto V.; Mancina R.M.; Pipitone R.; Karja V.; Maggioni M.; Kakela P.; Wiklund O.; Mozzi E.; Grimaudo S.; Kaminska D.; Rametta R.; Craxi A.; Fargion S.; Nobili V.; Romeo S.; Pihlajamaki J.; Valenti L.; Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015,63(3),705-712","journal-title":"J Hepatol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e000075","DOI":"10.1136\/bmjgast-2015-000075","volume":"3","author":"Nascimbeni F.","year":"2016","unstructured":"Nascimbeni F.; Aron-Wisnewsky J.; Pais R.; Tordjman J.; Poitou C.; Charlotte F.; Bedossa P.; Poynard T.; Cl\u00e9ment K.; Ratziu V.; Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol LIDO study Group2016,3(1),e000075","journal-title":"BMJ Open Gastroenterol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"Targher G.","year":"2010","unstructured":"Targher G.; Day C.P.; Bonora E.; Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010,363(14),1341-1350","journal-title":"N Engl J Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","volume":"27","author":"Del Ben M.","year":"2017","unstructured":"Del Ben M.; Baratta F.; Polimeni L.; Pastori D.; Loffredo L.; Averna M.; Violi F.; Angelico F.; Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2017,27(2),161-167","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5551\/jat.50039","volume":"27","author":"Cho Y.","year":"2020","unstructured":"Cho Y.; Lee H.; Park H.K.; Choe E.Y.; Wang H.J.; Kim R.H.; Kim Y.; Kang E.S.; Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo. J Atheroscler Thromb 2020,27(5),429-440","journal-title":"J Atheroscler Thromb"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e20202485","DOI":"10.1590\/0100-6991e-20202485","volume":"47","author":"Ott-Fontes P.R.","year":"2020","unstructured":"Ott-Fontes P.R.; Diedrich Neto J.A.; Goldoni M.B.; Comparison of the severity of non-alcoholic fatty liver disease in diabetic and non-diabetic obese patients. Rev Col Bras Cir 2020,47,e20202485","journal-title":"Rev Col Bras Cir"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","volume":"46","author":"Park H.","year":"2011","unstructured":"Park H.; Shima T.; Yamaguchi K.; Mitsuyoshi H.; Minami M.; Yasui K.; Itoh Y.; Yoshikawa T.; Fukui M.; Hasegawa G.; Nakamura N.; Ohta M.; Obayashi H.; Okanoue T.; Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011,46(1),101-107","journal-title":"J Gastroenterol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MOL.0b013e3283541cfc","volume":"23","author":"Wierzbicki A.S.","year":"2012","unstructured":"Wierzbicki A.S.; Oben J.; Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 2012,23(4),345-352","journal-title":"Curr Opin Lipidol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","volume":"57","author":"Takeshita Y.","year":"2014","unstructured":"Takeshita Y.; Takamura T.; Honda M.; Kita Y.; Zen Y.; Kato K.; Misu H.; Ota T.; Nakamura M.; Yamada K.; Sunagozaka H.; Arai K.; Yamashita T.; Mizukoshi E.; Kaneko S.; The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014,57(5),878-890","journal-title":"Diabetologia"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1517\/14740338.2015.1063613","volume":"14","author":"Husain N.E.","year":"2015","unstructured":"Husain N.E.; Hassan A.T.; Elmadhoun W.M.; Ahmed M.H.; Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? Expert Opin Drug Saf 2015,14(9),1445-1455","journal-title":"Expert Opin Drug Saf"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","volume":"270","author":"Simon T.G.","year":"2018","unstructured":"Simon T.G.; Corey K.E.; Cannon C.P.; Blazing M.; Park J.G.; O\u2019Donoghue M.L.; Chung R.T.; Giugliano R.P.; The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018,270,245-252","journal-title":"Int J Cardiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2174\/1381612824666180604113653","volume":"24","author":"Doumas M.","year":"2018","unstructured":"Doumas M.; Imprialos \u039a.; Stavropoulos K.; Reklou A.; Sachinidis A.; Athyros V.G.; Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. Curr Pharm Des 2018,24(17),1879-1886","journal-title":"Curr Pharm Des"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2174\/1570161114666160909161811","volume":"14","author":"Athyros V.G.","year":"2016","unstructured":"Athyros V.G.; Katsiki N.; Karagiannis A.; Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? Curr Vasc Pharmacol 2016,14(6),494-497","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1060028020935105","volume":"55","author":"Dougherty J.A.","year":"2021","unstructured":"Dougherty J.A.; Guirguis E.; Thornby K.A.; A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Ann Pharmacother 2021,55(1),65-79","journal-title":"Ann Pharmacother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","year":"2016","unstructured":"EASL-EASD-EASO clinical practice guidelines for the management of non alcoholic fatty liver disease. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). J Hepatol 2016,64,1388-1402","journal-title":"J Hepatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/157016111705190703102816","volume":"17","author":"Doumas M.","year":"2019","unstructured":"Doumas M.; Imprialos K.; Stavropoulos K.; Athyros V.G.; What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? Curr Vasc Pharmacol 2019,17(5),425-428","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-230X-12-2","volume":"12","author":"Sumida Y.","year":"2012","unstructured":"Sumida Y.; Yoneda M.; Hyogo H.; Itoh Y.; Ono M.; Fujii H.; Eguchi Y.; Suzuki Y.; Aoki N.; Kanemasa K.; Fujita K.; Chayama K.; Saibara T.; Kawada N.; Fujimoto K.; Kohgo Y.; Yoshikawa T.; Okanoue T.; Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)2012,12,2","journal-title":"BMC Gastroenterol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"Baratta F","year":"2020","unstructured":"Baratta F; Pastori D; Angelico F; Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. Clin Gastroenterol Hepatol 2020,18(10),2324-2331","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ndt\/gfl538","volume":"22","author":"Athyros V.G.","year":"2007","unstructured":"Athyros V.G.; Mikhailidis D.P.; Liberopoulos E.N.; Kakafika A.I.; Karagiannis A.; Papageorgiou A.A.; Tziomalos K.; Ganotakis E.S.; Elisaf M.; Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007,22(1),118-127","journal-title":"Nephrol Dial Transplant"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1185\/03007990802069563","volume":"24","author":"Athyros V.G.","year":"2008","unstructured":"Athyros V.G.; Kakafika A.I.; Papageorgiou A.A.; Paraskevas K.I.; Tziomalos K.; Anagnostis P.; Pagourelias E.; Koumaras C.; Karagiannis A.; Mikhailidis D.P.; Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Curr Med Res Opin 2008,24(6),1593-1599","journal-title":"Curr Med Res Opin"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","volume":"71","author":"Athyros V.G.","year":"2017","unstructured":"Athyros V.G.; Alexandrides T.K.; Bilianou H.; Cholongitas E.; Doumas M.; Ganotakis E.S.; Goudevenos J.; Elisaf M.S.; Germanidis G.; Giouleme O.; Karagiannis A.; Karvounis C.; Katsiki N.; Kotsis V.; Kountouras J.; Liberopoulos E.; Pitsavos C.; Polyzos S.; Rallidis L.S.; Richter D.; Tsapas A.G.; Tselepis A.D.; Tsioufis K.; Tziomalos K.; Tzotzas T.; Vasiliadis T.G.; Vlachopoulos C.; Mikhailidis D.P.; Mantzoros C.; The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017,71,17-32","journal-title":"Metabolism"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1567-5688(14)70002-9","volume":"16","author":"Arnaboldi L.","year":"2015","unstructured":"Arnaboldi L.; Corsini A.; Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl 2015,16,1-27","journal-title":"Atheroscler Suppl"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","volume":"63","author":"Brouwers M.C.G.J.","year":"2020","unstructured":"Brouwers M.C.G.J.; Simons N.; Stehouwer C.D.A.; Isaacs A.; Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia 2020,63(2),253-260","journal-title":"Diabetologia"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e00179","DOI":"10.1002\/edm2.179","volume":"3","author":"Tavaglione F","year":"2020","unstructured":"Tavaglione F; Targher G; Valenti L; Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diab Metab 2020,3(4),e00179","journal-title":"Endocrinol Diab Metab"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"101049","DOI":"10.1016\/j.molmet.2020.101049","author":"Mahjoubin-Tehran M.","year":"2021","unstructured":"Mahjoubin-Tehran M.; De Vincentis A.; Mikhailidis D.P.; Atkin S.L.; Mantzoros C.S.; Jamialahmadi T.; Sahebkar A.; Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab 2021,101049","journal-title":"Mol Metab"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1007\/s10620-020-06505-x","volume":"65","author":"Athyros V.G.","year":"2020","unstructured":"Athyros V.G.; Katsiki N.; Mikhailidis D.P.; NAFLD and Statins. Dig Dis Sci 2020,65(10),3052-3053","journal-title":"Dig Dis Sci"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/186906","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186906\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/186906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:28:23Z","timestamp":1643779703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186906\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161118666201015152921","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}